首页 | 本学科首页   官方微博 | 高级检索  
     


CD99 reactivity in mesenchymal chondrosarcoma
Authors:Scott R. Granter MD   Andrew A. Renshaw MD   Christopher D. M. Fletcher MD   MRCPath   Atul K. Bhan MD  Andrew E. Rosenberg MD
Affiliation:Departments of Pathology, Brigham &; Women's Hospital, Massachusetts General Hospital, and Harvard Medical School, Boston, MA USA
Abstract:CD99 reactivity has been reported to be a sensitive and specific marker for Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET). However, within the group of “small round blue cell tumors,” the specificity has not been extensively examined. We investigated the immunoreactivity of mesenchymal chondrosarcoma to CD99 using the 013 antibody and found reactivity in 11 of 11 (100%) of cases, specifically in the “small round blue cell” component. All cases showed strong reactivity involving more than 50% of the small round blue cells with a distinct membrane pattern of staining. Staining was either absent or focal and weak in cartilaginous areas. We conclude that mesenchymal chondrosarcoma cannot be distinguished from ES/PNET on the basis of CD99 immunoreactivity.
Keywords:MIC2   013   CD99   immunohistochemistry   mesenchymal chondrosarcoma   Ewing's sarcoma   primitive neuroectodermal tumors
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号